Latest long-term debt for RDHL: $860K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Redhill Biopharma (RDHL) currently reports a long-term debt of $860K as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Redhill Biopharma's long-term debt history and peer comparisons.
Redhill Biopharma's long-term debt changed from $0 to $860K (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Redhill Biopharma reported $860K in long-term debt as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current long-term debt of $860K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Redhill Biopharma, and consider following RDHL for alerts when major investors trade the stock.
Redhill Biopharma is classified in the Healthcare sector. On long-term debt, it currently shows $860K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RDHL with unrelated industries.